STOCKHOLM, March 14, 2023 /PRNewswire/ BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing coverage
/PRNewswire/ BioArctic AB s (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the U.S. Veterans Health Administration (VHA) is providing.
Confirmatory Phase 3 Clarity AD data to be evaluated by FDA in determining whether to convert accelerated approval of LEQEMBI to a traditional approval Priority Review accelerates FDA review time with